Paul Dorian

Paul Dorian

Auto-generated profile, based on publicly available information

Paul Dorian

Division of Cardiology, Unity Health Toronto – St. Michael’s Hospital

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
CLCameron H. Landry
Cameron H. Landry
KAKatherine S. Allan
Katherine S. Allan
KCKim A. Connelly
Kim A. Connelly
KCKris Cunningham
Kris Cunningham
LMLaurie J. Morrison
Laurie J. Morrison
PDPaul Dorian
Paul Dorian
The incidence of sudden cardiac arrest during participation in sports activities remains unknown. Preparticipation screening programs aimed at preventing sudden cardiac arrest during sports activities are thought to be able to identify at-risk athletes; however, the efficacy of these programs remains controversial. We sought to identify all sudden cardiac arrests that occurred during participation in sports activities within a specific region of Canada and to determine their causes.

15 December 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
PMPurav Mody
Purav Mody
APAmbarish Pandey
Ambarish Pandey
ASArthur S. Slutsky
Arthur S. Slutsky
MSMatthew W. Segar
Matthew W. Segar
AKAlex Kiss
Alex Kiss
LMLaurie Morrison
Laurie Morrison
Background: Studies examining gender-based differences in outcomes of patients experiencing out-of-hospital cardiac arrest have demonstrated that, despite a higher likelihood of return of spontaneous circulation, women do not have higher survival. Methods: Patients successfully resuscitated from out-of-hospital cardiac arrest enrolled in the CCC trial (Trial of Continuous or Interrupted Chest Compressions during CPR) were included. Hierarchical multivariable logistic regression models were constructed to evaluate the association between gender and survival after adjustment for age, gender, cardiac arrest rhythm, witnessed status, bystander cardiopulmonary resuscitation, episode location, epinephrine dose, emergency medical services response time, and duration of resuscitation. Do not resuscitate (DNR) and withdrawal of life-sustaining therapy (WLST) order status were used to assess whether differences in postresuscitation outcomes were modified by baseline prognosis. The analysis was replicated among ALPS trial (Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest) participants. Results: Among 4875 successfully resuscitated patients, 1825 (37.4%) were women and 3050 (62.6%) were men. Women were older (67.5 versus 65.3 years), received less bystander cardiopulmonary resuscitation (49.1% versus 54.9%), and had a lower proportion of cardiac arrests that were witnessed (55.1% versus 64.5%) or had shockable rhythm (24.3% versus 44.6%, P <0.001 for all). A significantly higher proportion of women received DNR orders (35.7% versus 32.1%, P =0.009) and had WLST (32.8% versus 29.8%, P =0.03). Discharge survival was significantly lower in women (22.5% versus 36.3%, P <0.001; adjusted odds ratio, 0.78 [95% CI, 0.66–0.93]; P =0.005). The association between gender and survival to discharge was modified by DNR and WLST order status such that women had significantly reduced survival to discharge among patients who were not designated DNR (31.3% versus 49.9%, P =0.005; adjusted odds ratio, 0.74 [95% CI, 0.60–0.91]) or did not have WLST (32.3% versus 50.7%, P =0.002; adjusted odds ratio, 0.73 [95% CI, 0.60–0.89]). In contrast, no gender difference in survival was noted among patients receiving a DNR order (6.7% versus 7.4%, P =0.90) or had WLST (2.8% versus 2.4%, P =0.93). Consistent patterns of association between gender and postresuscitation outcomes were observed in the secondary cohort. Conclusions: Among patients resuscitated after experiencing out-of-hospital cardiac arrest, discharge survival was significantly lower in women than in men, especially among patients considered to have a favorable prognosis.

1 August 2013 in American Heart Journal
Verified
Journal Article
Closed access
PDPaul Dorian
Paul Dorian
CBCaroline Burk
Caroline Burk
CMChristopher M. Mullin
Christopher M. Mullin
RBRosemary Bubien
Rosemary Bubien
DGDonna Godejohn
Donna Godejohn
JSJohn Spertus
John Spertus

9 February 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
PDPaul Dorian
Paul Dorian
TKThitima Kongnakorn
Thitima Kongnakorn
HPHemant Phatak
Hemant Phatak
DRDale A. Rublee
Dale A. Rublee
AKAndreas Kuznik
Andreas Kuznik
GLGregory Y.H. Lip
Gregory Y.H. Lip
Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients and those unsuitable for warfarin. Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin. We evaluated the potential cost-effectiveness of apixaban against warfarin and aspirin from the perspective of the UK payer perspective. A lifetime Markov model was developed to evaluate the pharmacoeconomic impact of apixaban compared with warfarin and aspirin in VKA suitable and VKA unsuitable patients, respectively. Clinical events considered in the model include ischaemic stroke, haemorrhagic stroke, intracranial haemorrhage, other major bleed, clinically relevant non-major bleed, myocardial infarction, cardiovascular hospitalization and treatment discontinuations; data from the ARISTOTLE and AVERROES trials and published mortality rates and event-related utility rates were used in the model. Apixaban was projected to increase life expectancy and quality-adjusted life years (QALYs) compared with warfarin and aspirin. These gains were expected to be achieved at a drug acquisition-related cost increase over lifetime. The estimated incremental cost-effectiveness ratio was £11 909 and £7196 per QALY gained with apixaban compared with warfarin and aspirin, respectively. Sensitivity analyses indicated that results were robust to a wide range of inputs. Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.

30 August 2023 in European Heart Journal
Verified
Journal Article
Closed access
HBHifza Buhari
Hifza Buhari
JFJiming Fang
Jiming Fang
LHLu Han
Lu Han
PAPeter C Austin
Peter C Austin
PDPaul Dorian
Paul Dorian
HAHusam Abdel-Qadir
Husam Abdel-Qadir
Background and aims: Female sex is associated with higher rates of stroke in atrial fibrillation (AF) after adjustment for other CHA2DS2-VASc factors. This study aimed to describe sex differences in age and cardiovascular care to examine their relationship with stroke hazard in AF. Methods: Population-based cohort study using administrative datasets of people aged ≥66 years diagnosed with AF in Ontario between 2007 and 2019. Cause-specific hazard regression was used to estimate the adjusted hazard ratio (HR) for stroke associated with female sex over a 2-year follow-up. Model 1 included CHA2DS2-VASc factors, with age modelled as 66–74 vs. ≥ 75 years. Model 2 treated age as a continuous variable and included an age–sex interaction term. Model 3 further accounted for multimorbidity and markers of cardiovascular care. Results: The cohort consisted of 354 254 individuals with AF (median age 78 years, 49.2% female). Females were more likely to be diagnosed in emergency departments and less likely to receive cardiologist assessments, statins, or LDL-C testing, with higher LDL-C levels among females than males. In Model 1, the adjusted HR for stroke associated with female sex was 1.27 (95% confidence interval 1.21–1.32). Model 2 revealed a significant age–sex interaction, such that female sex was only associated with increased stroke hazard at age >70 years. Adjusting for markers of cardiovascular care and multimorbidity further decreased the HR, so that female sex was not associated with increased stroke hazard at age ≤80 years. Conclusion: Older age and inequities in cardiovascular care may partly explain higher stroke rates in females with AF.

1 November 2012 in Resuscitation
Verified
Journal Article
Closed access
BGBenedict M. Glover
Benedict M. Glover
SBSiobhan P. Brown
Siobhan P. Brown
LMLaurie Morrison
Laurie Morrison
DDDaniel Davis
Daniel Davis
PKPeter J. Kudenchuk
Peter J. Kudenchuk
PDPaul Dorian
Paul Dorian